Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Buy

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Strong Sell

Analyst Rating

Sell

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Neutral

Standard Deviation

Strong Sell

Williams %R

Strong Buy

Average Directional Index

Sell

Insider Trading

Neutral

Wall Street Data Solutions Rating

Neutral

B

LiveOne, Inc. Common Stock (LVO)

Retail-eating Places

https://www.liveone.com

LiveOne Inc, formerly LiveXLive Media Inc is a premium internet network devoted to live music and music-related video content. The company has been building an online destination for music fans to enjoy live performances from music venues and music festivals around the world, such as Rock in Rio, Outside Lands Music and Arts Festival, and Hangout Music Festival, as well as original content, artist exclusives, and industry interviews. The Company operates mainly through two segments, Audio and Media, with a majority of its revenue derived from the Audio segment.

9200 SUNSET BOULEVARD, SUITE #1201
WEST HOLLYWOOD, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

04/29/2011

Market Cap

166,258,160

Shares Outstanding

91,180,000

Weighted SO

87,944,495

Total Employees

N/A

Upcoming Earnings

08/08/2024

Similar Tickers

RDIB --.--%

MCS --.--%

RDI --.--%

NWS --.--%

RSVR --.--%

NWSA --.--%

BATRA --.--%

FWONA --.--%

WMG --.--%

Beta

1.6370

Last Div

0.0000

Range

0.84-2.19

Chg

0.0201

Avg Vol

446837

Mkt Cap

166258160

Exch

NASDAQ

Country

US

Phone

310 601 2505

DCF Diff

N/A

DCF

0.0000

Div Yield

0.0000

P/S

1.3435

EV Multiple

-81.2314

P/FV

-41.6473

Div Yield %

0.0000

P/E

-13.3700

PEG

-0.3515

Payout

-0.2746

Current Ratio

0.5319

Quick Ratio

0.4735

Cash Ratio

0.1313

DSO

43.5345

DIO

10.6759

Op Cycle

54.2105

DPO

54.4933

CCC

-0.2828

Gross Margin

0.2239

Op Margin

-0.0407

Pretax Margin

-0.1039

Net Margin

-0.0959

Eff Tax Rate

-0.0068

ROA

-0.1836

ROE

2.6311

ROCE

-0.3056

NI/EBT

0.9229

EBT/EBIT

2.5523

EBIT/Rev

-0.0407

Debt Ratio

0.1283

D/E

-2.1769

LT Debt/Cap

-0.1873

Total Debt/Cap

1.8497

Int Coverage

2.4825

CF/Debt

0.1081

Equity Multi

-16.9674

Rec Turnover

8.3841

Pay Turnover

6.6981

Inv Turnover

34.1890

FA Turnover

33.3019

Asset Turnover

1.9148

OCF/Share

0.0095

FCF/Share

-0.0345

Cash/Share

0.0669

OCF/Sales

0.0072

FCF/OCF

-3.6373

CF Coverage

0.1081

ST Coverage

0.1165

CapEx Coverage

0.2156

Div&CapEx Cov

0.1209

P/BV

-41.6473

P/B

-41.6473

P/S

1.3435

P/E

-13.3700

P/FCF

-51.0151

P/OCF

177.0475

P/CF

177.0475

PEG

-0.3515

P/S

1.3435

EV Multiple

-81.2314

P/FV

-41.6473

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jun 05, 02:29 Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million GlobeNewswire Inc. Jun 04, 23:55 Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million GlobeNewswire Inc. Jun 04, 23:55 Alvotech lýkur lokuðu útboði á alls 7.500.000 sænskum heimildarskírteinum (SDR) og hlutabréfum á genginu 100 sænskar krónur fyrir hvert SDR og 1.320,83 íslenskar krónur fyrir hvern hlut, að heildarfjárhæð 750 milljónir sænskra króna GlobeNewswire Inc. May 26, 18:06 Aðalfundur Alvotech boðaður 25. júní 2025 GlobeNewswire Inc. May 26, 18:06 Alvotech Annual General Meeting to be held June 25, 2025 GlobeNewswire Inc. Mar 26, 22:36 Alvotech birtir metuppgjör fyrir árið 2024, sem sýnir mikla tekjuaukningu og kynnir nýjar áherslur og áfanga í rekstri félagsins GlobeNewswire Inc. May 21, 00:25 Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S. GlobeNewswire Inc. May 21, 00:25 Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S. GlobeNewswire Inc. May 21, 00:25 Alvotech og Teva Pharmaceuticals hefja sölu á líftæknilyfjahliðstæðunni Simlandi í Bandaríkjunum GlobeNewswire Inc. Jan 19, 11:30 Alvotech birtir upplýsingar um stöðu umsókna um markaðsleyfi fyrir AVT02 og AVT04 í Bandaríkjunum GlobeNewswire Inc. Jan 19, 11:30 Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04 GlobeNewswire Inc. Jan 19, 11:30 Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04 GlobeNewswire Inc. Jan 16, 12:30 LiveOne (NASDAQ: LVO) Announces Milestone Revenues GlobeNewswire Inc. Jan 10, 03:30 Alvotech og STADA hljóta markaðsleyfi fyrir fyrstu líftæknilyfjahliðstæðuna við Stelara í Evrópu GlobeNewswire Inc. Jan 10, 03:30 STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara GlobeNewswire Inc. Jan 10, 03:30 STADA and Alvotech Secure Approval for Uzpruvo, Europe’s First Ustekinumab Biosimilar to Stelara GlobeNewswire Inc. Jan 10, 03:30 Alvotech og STADA hljóta markaðsleyfi fyrir fyrstu líftæknilyfjahliðstæðuna við Stelara í Evrópu GlobeNewswire Inc. Jan 10, 03:30 STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara GlobeNewswire Inc. Jan 10, 03:30 STADA and Alvotech Secure Approval for Uzpruvo, Europe’s First Ustekinumab Biosimilar to Stelara GlobeNewswire Inc. Jan 03, 03:30 Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea® (aflibercept)

Revenue Product Segmentation